Core Viewpoint - Whitehawk Therapeutics Inc. announced a multi-year collaboration with Tempus AI aimed at advancing biomarker-driven research, which has influenced its stock performance despite a recent drop in after-hours trading [2]. Group 1: Collaboration Details - The partnership with Tempus AI will utilize its proprietary real-world dataset to support the development of Whitehawk's oncology pipeline [2]. - The collaboration announcement gained traction on social media, indicating potential investor interest and market engagement [2]. Group 2: Recent Earnings Performance - Whitehawk reported a loss of $0.76 per share for the second quarter, missing expectations of a $0.09 gain, and reported no revenue for the quarter, falling short of the $60 million estimate [3]. - The next earnings report is scheduled for November 15 [3]. Group 3: Stock Performance - Whitehawk's shares have gained 21.96% over the past year and risen 33.85% in the past month, although the stock is down 17.41% year-to-date in 2025 [4]. - The market capitalization of Whitehawk is $122.42 million, with shares trading between $1.39 and $3.81 over the past year and an average daily trading volume of about 118,820 shares [4]. Group 4: Stock Trend Analysis - Benzinga Edge Stock Rankings indicate that WHWK has a positive price trend across all time frames, suggesting favorable market sentiment [5].